VRTX Related Analyst PT Change
-
Vertex (VRTX) PT Goes to $95 at Needham & Company after Strong Data
-
Goldman Sachs Upgrades Vertex (VRTX) to Neutral after 661/Kalydeco Combo Data
-
Canaccord Genuity Upgrades Vertex (VRTX) to Buy
-
Goldman Says Expect More Downside in Vertex Pharmaceuticals (VRTX)
-
Goldman Sachs Downgrades Vertex (VRTX) to Sell; Becomes More Cautious on CF Combo Program
-
UBS on U.S. Biotechnology - Updating Outlook on Covered Stocks (GILD, AMGN, BIIB, CELG, INCY, IDIX, VRTX, SGEN)
-
Barclays Lowers Outlook on Idenix Pharmaceuticals (IDIX); Clarity on FDA Clinical Hold (BMY, VRTX, GILD)
-
UBS Cuts Estimates on Vertex (VRTX): Keep 'Buy' Thesis and Bullish View
-
RBC Capital Downgrades Vertex (VRTX) to Outperform
-
Leerink Swann Maintains an 'Outperform' on Vertex (VRTX); CF Conference Call Affirms Opportunity
-
Barclays Maintains an 'Overweight' on Vertex (VRTX); Raising PT to $77
-
Wells Fargo Upgrades Vertex (VRTX) to Outperform; Compelling CF Combo Data
-
ISI Group Upgrades Vertex (VRTX) to Buy
-
UBS Maintains a 'Neutral' on Vertex (VRTX); Potential CF Program Advancement
Back to VRTX Stock Lookup
